Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) for BALVERSA? (erdafitinib), marking a significant development in cancer treatment. The approval targets adult patients with locally advanced or metastatic urothelial carcinoma (mUC) harboring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations. These are individuals whose disease has progressed after at least one prior systemic therapy. The FDA's decision converts the drug's accelerated approval in April 2019 to a full approval, backed by substantial clinical evidence, particularly from the Phase 3 THOR study.

Approximately 20 percent of mUC patients exhibit FGFR3 genetic alterations, constituting a significant target population. Following previous systemic treatments, including checkpoint inhibitors, these patients typically face grim prognoses with limited therapeutic avenues. The approval is rooted in the outcomes of Cohort 1 of the Phase 3 THOR study, affirming BALVERSA?'s efficacy in prolonging overall survival compared to chemotherapy in the second-line setting. Results showcased a notable 36 percent decrease in the risk of death with BALVERSA? versus chemotherapy among patients previously treated with PD-1 or PD-(L)1 inhibitors.

Dr. Kiran Patel, Vice President of Clinical Development for Solid Tumors at Johnson & Johnson Innovative Medicine, commented on the significance of this milestone. He emphasized BALVERSA?'s role in advancing precision therapies in oncology, particularly in addressing advanced bladder cancer.

The U.S. Prescribing Information for BALVERSA? outlines warnings and precautions, including ocular disorders, hyperphosphatemia, and embryo-fetal toxicity. Common adverse reactions (>20%) encompass various laboratory abnormalities and physical symptoms.

Johnson & Johnson is facilitating access to BALVERSA? and related patient services through a designated specialty pharmacy provider, US Bioservices. This streamlined approach underscores the company's ongoing dedication to delivering top-tier products, services, and support to healthcare professionals and patients alike.